Table 1 Comparison about the demographic and clinical features between NMOSD-NOSIS patients with different developments
Total n = 43 | NMOSD-NOSIS developing ON/MY n = 38 | NMOSD-NOSIS restricted in non-ON/MY n = 5 | P value | |||
|---|---|---|---|---|---|---|
Age of onset, y, median(IQR) | 28.00(21.00–37.00) | 28.00(20.75–35.50) | 26.00(22.50–42.00) | 0.652 | ||
Female, n(%) | 38(88.37) | 33(86.84) | 5(100) | 0.904 | ||
AQP4-IgG+, n(%) | 36 (83.72 ) | 32 (84.21 ) | 4 (80.00) | 0.811 | ||
ARR, median(IQR) | 0.75(0.50–1.27) | 0.75(0.50–1.25) | 0.67(0.48–3.00) | 0.657 | ||
Coexisting autoimmunity, n(%) | 6 (13.95) | 5 (13.16) | 1 (20.00) | 0.592 | ||
CSF leukocyte cell count, n/ul, median(IQR) | 0.30(0–4.00) | 3.00(0–4.00) | 1.00(0–14.00) | 0.983 | ||
CSF protein, mg/L, mean(SD) | 0.26 ± 0.13 | 0.26 ± 0.14 | 0.26 ± 0.11 | 0.980 | ||
EDSS at onset, median(IQR) | 0(0–2.00) | 0(0–2.00) | 2.00(1.00–2.00) | 0.356 | ||
EDSS at follow-up, median(IQR) | 2.50(2.00–3.00) | 2.75(1.75–3.00) | 2.00(1.00–3.75) | 0.622 | ||
Follow-up, y, median(IQR) | 5.00(3.00–8.00) | 5.50(3.00–8.25) | 3.00(1.00–5.00) | 0.042 | ||